240 GSK Annual Report 2016 Financial record Quarterly trend An unaudited analysis of the Group results is provided by quarter in Sterling for the financial year 2016.
Income statement total 12 months 2016 Q4 2016 Reported Reported Pro-forma m CER% % CER% m CER% % Turnover Pharmaceuticals 16,104 314 4 4,575 422 Vaccines 4,592 14 26 12 1,137 18 Consumer Healthcare 7,193 919 5 1,874 220 27,889 617 5 7,586 321 Corporate and other unallocated turnover Total turnover 27,889 617 5 7,586 321 Cost of sales 9,290 1 5 2,508 9 1 Selling, general and administration 9,366 6 1 2,711 7 9 Research and development 3,628 6 2 1,003 16 5 Royalty income 398 16 21 117 22 29 Other operating income 3,405 886 Operating profit loss 2,598 86 75 595 100 100 Net finance costs 664 173 Share of after tax profits losses of associates and joint ventures 51 profit loss before taxation 1,939 92 82 423 100 100 Taxation 877 106 Tax rate % 45.2% 25.1% profit loss after taxation for the period 1,062 98 87 317 97 100 profit loss attributable to non-controlling interests 150 60 profit loss attributable to shareholders 912 257 Basic earnings loss per share pence 18.8p 99 89 5.3p 100 100 Diluted earnings loss per share pence 18.6p 5.2p Income statement core Total turnover 27,889 617 5 7,586 321 Cost of sales 8,351 511 3 2,195 2 6 Selling, general and administration 8,697 210 2,429 1 15 Research and development 3,468 312 3 1,017 620 Royalty income 398 16 21 17 117 22 29 Operating profit 7,771 14 36 17 2,062 16 52 Net finance costs 652 170 Share of after tax profits losses of associates and joint ventures 51 profit before taxation 7,124 16 40 1,893 18 58 Taxation 1,509 410 Tax rate % 21.2% 21.7% profit after taxation for the period 5,615 14 37 1,483 12 51 profit attributable to non-controlling interests 637 212 profit attributable to shareholders 4,978 1,271 Adjusted earnings per share pence 102.4p 12 35 26.1p 11 45 The calculation of core results is described on page 57.
% represents growth at actual exchange rates.
